Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

Description

The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the development of lung disease.

Conditions

Rheumatoid Arthritis, Interstitial Lung Disease

Study Overview

Study Details

Study overview

The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the development of lung disease.

Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease

Condition
Rheumatoid Arthritis
Intervention / Treatment

-

Contacts and Locations

Aurora

University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States, 80045

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. ≥ 45years old
  • 2. Diagnosis of RA using the 2010 American College of Rheumatology (ACR) criteria
  • 1. Inability to give informed consent
  • 2. Pregnant women
  • 3. History of interstitial lung disease
  • 4. Evidence of other causes of diffuse parenchymal lung disease such as infection, drug toxicity, other autoimmune processes, etc.
  • 5. Subjects over the age of 90 years old or less than 45 years old

Ages Eligible for Study

45 Years to 90 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Colorado, Denver,

Joyce S Lee, MD, PRINCIPAL_INVESTIGATOR, University of Colorado, Denver

Study Record Dates

2027-06